Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2022
   Pooled it
2. Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.Clinical and translational science · 2021
   Trial
3. PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.bioRxiv : the preprint server for biology · 2026
   Article
4. Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities.Life (Basel, Switzerland) · 2025
   Review
5. Psoriasis: an update on topical and systemic therapies.Australian prescriber · 2025
   Review
6. Integration of Synchronizing In Silico, In Vitro, and In Vivo Strategies for the Development of Antipsoriatic Apremilast-loaded Nanostructured Lipid Carrier Embedded in Hydrogel.AAPS PharmSciTech · 2025
   Article
7. Surface Defects and Crystal Growth of Apremilast Benzoic Acid Cocrystals.Organic process research & development · 2025
   Article
8. Phthalimides: developments in synthesis and functionalization.RSC advances · 2024
   Review
9. Exploring Phthalimide as the Acid Component in the Passerini Reaction.Organic letters · 2024
   Article
10. Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review.Frontiers in immunology · 2024
    Review
11. Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment.Therapeutic delivery · 2024
    Article
12. Design, Synthesis, Biological Evaluation, and Molecular Docking Study of 4,6-Dimethyl-5-aryl/alkyl-2-[2-hydroxy-3-(4-substituted-1-piperazinyl)propyl]pyrrolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2023
    Article
13. Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis.Biologics : targets & therapy · 2023
    Article
14. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates.International journal of rheumatic diseases · 2022
    Review
15. Structure-property relations of a unique and systematic dataset of 19 isostructural multicomponent apremilast forms.IUCrJ · 2022
    Article
16. Protective roles of apremilast via Sirtuin 1 in atherosclerosis.Bioengineered · 2022
    Article
17. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.Medicina (Kaunas, Lithuania) · 2022
    Review
18. Development of Apremilast Nanoemulsion-Loaded Chitosan Gels: In Vitro Evaluations and Anti-Inflammatory and Wound Healing Studies on a Rat Model.Gels (Basel, Switzerland) · 2022
    Article
19. Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles.Computational and structural biotechnology journal · 2022
    Article
20. Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.Acta dermato-venereologica · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract